AR038900A1 - Moleculas similares al interferon beta para el tratamiento del derrame cerebral - Google Patents
Moleculas similares al interferon beta para el tratamiento del derrame cerebralInfo
- Publication number
- AR038900A1 AR038900A1 ARP030100791A ARP030100791A AR038900A1 AR 038900 A1 AR038900 A1 AR 038900A1 AR P030100791 A ARP030100791 A AR P030100791A AR P030100791 A ARP030100791 A AR P030100791A AR 038900 A1 AR038900 A1 AR 038900A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- interferon
- spill
- brain
- interferon beta
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 229960001388 interferon-beta Drugs 0.000 title 1
- 102000014150 Interferons Human genes 0.000 abstract 3
- 108010050904 Interferons Proteins 0.000 abstract 3
- 229940079322 interferon Drugs 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 101100179429 Homo sapiens IFNB1 gene Proteins 0.000 abstract 2
- 230000013595 glycosylation Effects 0.000 abstract 2
- 238000006206 glycosylation reaction Methods 0.000 abstract 2
- 102220594474 Annexin-2 receptor_L88T_mutation Human genes 0.000 abstract 1
- 102220627590 Coagulation factor IX_K45N_mutation Human genes 0.000 abstract 1
- 102220476665 Dynein axonemal assembly factor 10_S75T_mutation Human genes 0.000 abstract 1
- 230000004988 N-glycosylation Effects 0.000 abstract 1
- 102220480985 Nicotinate phosphoribosyltransferase_Q51N_mutation Human genes 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 102220486979 Sodium-dependent phosphate transport protein 1_S76N_mutation Human genes 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 102220603542 TYRO protein tyrosine kinase-binding protein_R27N_mutation Human genes 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 102220472118 Transmembrane protein_Q48N_mutation Human genes 0.000 abstract 1
- 102220487674 Uridine diphosphate glucose pyrophosphatase NUDT22_K19N_mutation Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 102220035366 rs281865432 Human genes 0.000 abstract 1
- 102200080720 rs4077515 Human genes 0.000 abstract 1
- 102220319623 rs71559180 Human genes 0.000 abstract 1
- 102220104696 rs879253900 Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de polipéptidos similares al interferón b para el tratamiento del derrame cerebral o del ataque isquémico transitorio en un primate, con preferencia en un humano. Más particularmente, los polipéptidos similares al interferón b difieren de la secuencia de aminoácidos del IFNB humano de tipo salvaje (SEC ID NO:2) en el hecho de que se ha introducido al menos un sitio de glicosilación, con preferencia se ha introducido al menos un sitio de N-glicosilación in vivo. En forma opcional, los polipéptidos similares al interferón b son PEGilados. Reivindicación 11: El uso de acuerdo con cualquiera de las reivindicaciones 1-10, en donde al menos un sitio de glicosilación se introduce por una sustitución seleccionada del grupo integrado por S2N+N4T/S, L9N+R11T/S, R11N, S12N+N14T/S, F15N+CI7S/T, Q16N+Q18T/S, K19N+L21T/S, Q23N+H25T/S, G26N+L28T/S, R27N+E29T/S, L28N+Y30T/S, D39T/S, K45N+L47T/S, Q46N+Q48T/S, Q48N+F50T/S, Q49N+Q51T/S, Q51N+E53T/S, R71N+D73T/S, Q72N, D73N, S75N, S76N+G78T/S, L88T/S, Y92T/S, N93N+I95T/S, L98T/S, E103N+K105T/S, E104N+L106T/S, E107N+E109T/S, K108N+D110T/S, D110N, F111N+R113T/S y L116N. Reivindicación 17: El uso de acuerdo con cualquiera de las reivindicaciones 1-16, en donde el residuo de cisteína ubicado en la posición 17 del IFNB humano de tipo salvaje (SEC ID NO:2) ha sido eliminado. Reivindicación 21: El uso de acuerdo con cualquiera de las reivindicaciones 1-20, en donde dicha variante comprende una sustitución en la posición 110.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200371 | 2002-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038900A1 true AR038900A1 (es) | 2005-02-02 |
Family
ID=27798724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100791A AR038900A1 (es) | 2002-03-12 | 2003-03-07 | Moleculas similares al interferon beta para el tratamiento del derrame cerebral |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060083715A1 (es) |
| EP (1) | EP1487478A2 (es) |
| JP (1) | JP2005519946A (es) |
| KR (1) | KR20040104504A (es) |
| AR (1) | AR038900A1 (es) |
| AU (1) | AU2003214019A1 (es) |
| CA (1) | CA2477577A1 (es) |
| IL (1) | IL163577A0 (es) |
| MX (1) | MXPA04008798A (es) |
| WO (1) | WO2003075944A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393934B2 (en) | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| PL1608400T3 (pl) | 2003-03-28 | 2010-11-30 | Faron Pharmaceuticals Oy | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 |
| CA2559809A1 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10 |
| MX2007001589A (es) * | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| JP4944112B2 (ja) * | 2005-08-26 | 2012-05-30 | アレス トレーディング ソシエテ アノニム | グリコシル化されたインターフェロンベータの調製方法 |
| FI20051003A0 (fi) * | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| JP2010525821A (ja) | 2007-05-02 | 2010-07-29 | アンブルックス，インコーポレイテッド | 修飾ＩＦＮβポリペプチドおよびこれらの使用 |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| EP2762489B1 (en) | 2011-10-01 | 2018-03-28 | Glytech, Inc. | Glycosylated polypeptide and pharmaceutical composition containing same |
| CN104334574B (zh) | 2013-03-29 | 2020-01-14 | 株式会社糖锁工学研究所 | 附加唾液酸化糖链的多肽 |
| EP3215178A4 (en) * | 2014-11-06 | 2018-07-25 | Yeda Research and Development Co. Ltd | Treatment of cns inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997018831A1 (en) * | 1995-11-17 | 1997-05-29 | Toray Industries, Inc. | Endothelial cell protective |
| JPH09151137A (ja) * | 1995-12-01 | 1997-06-10 | Toray Ind Inc | 平滑筋細胞増殖抑制剤 |
| DE60129472T2 (de) * | 2001-04-03 | 2008-04-17 | U-Cytech B.V. | Behandlung von hypoxya/ischaemia blutflusswiderstand mit beta-interferon |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| WO2002089828A2 (en) * | 2001-05-04 | 2002-11-14 | Institute Of Molecular And Cell Biology | Interferons in the treatment of ischemia |
-
2003
- 2003-02-28 MX MXPA04008798A patent/MXPA04008798A/es unknown
- 2003-02-28 EP EP03709664A patent/EP1487478A2/en not_active Withdrawn
- 2003-02-28 WO PCT/DK2003/000127 patent/WO2003075944A2/en not_active Ceased
- 2003-02-28 JP JP2003574217A patent/JP2005519946A/ja not_active Withdrawn
- 2003-02-28 CA CA002477577A patent/CA2477577A1/en not_active Abandoned
- 2003-02-28 AU AU2003214019A patent/AU2003214019A1/en not_active Abandoned
- 2003-02-28 KR KR10-2004-7014245A patent/KR20040104504A/ko not_active Withdrawn
- 2003-02-28 IL IL16357703A patent/IL163577A0/xx unknown
- 2003-02-28 US US10/506,954 patent/US20060083715A1/en not_active Abandoned
- 2003-03-07 AR ARP030100791A patent/AR038900A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060083715A1 (en) | 2006-04-20 |
| IL163577A0 (en) | 2005-12-18 |
| AU2003214019A1 (en) | 2003-09-22 |
| WO2003075944A2 (en) | 2003-09-18 |
| WO2003075944A3 (en) | 2004-03-18 |
| KR20040104504A (ko) | 2004-12-10 |
| CA2477577A1 (en) | 2003-09-18 |
| JP2005519946A (ja) | 2005-07-07 |
| EP1487478A2 (en) | 2004-12-22 |
| MXPA04008798A (es) | 2004-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038900A1 (es) | Moleculas similares al interferon beta para el tratamiento del derrame cerebral | |
| CO5700785A2 (es) | Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal | |
| DK1877435T3 (da) | Glucagon-lignende peptid 2 (GLP-2)-analoger | |
| AR039231A1 (es) | Agentes de union ox40r novedosos | |
| RU99106518A (ru) | Glp-1 производные | |
| CY1113850T1 (el) | Νεα παραγωγα ινσουλινης | |
| EP1548028A4 (en) | SUBSTITUTED WT1 PEPTIDES | |
| ATE544461T1 (de) | Rekonstituierte tenside mit verbesserten eigenschaften | |
| PE27897A1 (es) | Variantes bpn` que tienen absorbion disminuida e hidrolisis aumentada, en donde se sustituye una o mas regiones de enlace | |
| NO20075708L (no) | Pegylert G-CSF-polypeptider og fremgangsmater for fremstilling av samme | |
| PE20040834A1 (es) | ISOMEROS POSICIONALES DEL IFN PEG ALFA 2a | |
| DE170917T1 (de) | Neues derivat des humangammainterferon-polypeptids. | |
| PE20030974A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
| ATE536878T1 (de) | Herstellung einer therapeutischen zusammensetzung | |
| DE602004027508D1 (de) | Lpa-haltige verbindungen | |
| AR020066A1 (es) | Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican | |
| ECSP066495A (es) | Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) | |
| BRPI0411820A (pt) | composição farmacêutica | |
| ATE105841T1 (de) | 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen. | |
| FI894092A0 (fi) | Nya peptidasinhibitorer. | |
| NO20060675L (no) | Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider | |
| AR026068A1 (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia. | |
| ATE458490T1 (de) | Neues verfahren und neue zusammensetzung zur hemmung der angiogenese und des tumorwachstums unter verwendung von verbindungen auf basis einer sequenz in mmp-2 | |
| DE60018937D1 (de) | Somatostatin analoge und deren verwendung zur behandlung von krebs | |
| BR0316740A (pt) | ácido nucléico compreendendo uma sequência codificando um polipeptìdeo de glutenina modificada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |